Ipriflavone and low doses of estrogens in the prevention of bone mineral loss in climacterium
- 31 October 1992
- journal article
- clinical trial
- Published by Elsevier in Bone and Mineral
- Vol. 19, S49-S56
- https://doi.org/10.1016/0169-6009(92)90866-c
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Ipriflavone inhibits osteoclast differentiation in parathyroid transplanted parietal bone of ratsCalcified Tissue International, 1992
- Effects of ipriflavone and its metabolites on a clonal osteoblastic cell lineJournal of Bone and Mineral Research, 1991
- Evidence of Estrogen Receptors in Normal Human Osteoblast-Like CellsScience, 1988
- Estrogen Binding, Receptor mRNA, and Biologic Response in Osteoblast-Like Osteosarcoma CellsScience, 1988
- Overview of the efficacy of hormonal replacement therapyAmerican Journal of Obstetrics and Gynecology, 1987
- Estrogen therapy in the prevention and management of osteoporosisAmerican Journal of Obstetrics and Gynecology, 1987
- Estrogen Replacement TherapyClinical Obstetrics and Gynecology, 1986
- Effect of ipriflavone on glucocorticoid-induced osteoporosis in ratsLife Sciences, 1986
- Effects of Estrogens and Progestins on the Biochemistry and Morphology of the Postmenopausal EndometriumNew England Journal of Medicine, 1981
- Effects of long-term estrogen replacement therapyAmerican Journal of Obstetrics and Gynecology, 1979